A mathematical model of Bcr-Abl autophosphorylation, signaling through the Crkl pathway, and Gleevec dynamics in chronic myeloid leukemia

Discrete and Continuous Dynamical Systems - Series B

Volumn 4, Issue 1, 2004, Pages 99-114

  Charusanti, Pep ^a   Hu, Xiao ^a   Chen, Luonan ^a   Neuhauser, Daniel ^a   DiStefano III, Joseph J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autophosphorylation; Bcr abl; Chronic myeloid leukemia; Clearance; Gleevec

Indexed keywords

EID: 1142297294     PISSN: 15313492     EISSN: None     Source Type: Journal    
DOI: 10.3934/dcdsb.2004.4.99     Document Type: Conference Paper

References (52)

1. Aszalos, A. and D. D. ROSS, Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res. 18 (1998), 2937-2944.
2. Bard, Y. Nonlinear Parameter Estimation, Academic Press, New York, 1974.
3. Barnes, D. J. and J. V. Melo, Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia, Acta Haematol. 108 (2002), 180-202.
4. Branch, M. A., T. F. Coleman, and Y. Li, A subspace, interior, and conjugate gradient method for large-scale bound-constrained minimization problems, SIAM J. Sci. Comput. 21 (1999), 1-23.
5. Brasher, B. B. and R. A. Van Etten, c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines, J. Biol. Chem. 45 (2000), 35631-35637.
6. Buchdunger, E., C. L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, B. J. Druker, and N. B. Lydon, Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors, J. Pharmacol. Exp. Ther. 295 (2000), 139-145.
7. Carter, A., E. J. Dann, T. Katz, Y. Shechter, A. Oliven, R. Regev, E. Eytan, J. M. Rowel and G. D. Eytan, Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1, Br. J. Haematol. 114 (2001), 581-590.
8. Chai, S. K., G. L. Nichols, and P. Rothman, Constitutive activation of JAKs and STATs in Bcr-Abl expressing cell lines and peripheral blood cells derived from leukemic patients, J. Immunol 159 (1997), 4720-4728.
9. Chen, G., M. D. Porter, J. R. Bristol, M. J. Fitzgibbon, and S. Pazhanisamy, Kinetic mechanism of the p38-alpha MAP kinase: phosphoryl transfer to synthetic peptides, Biochemistry 39 (2000), 2079-2087.
10. Chopra, R., Q. Q. Pu, and A. G. Elefanty, Biology of Bcr-Abl, Blood Rev. 13 (1999), 211-229.
11. Cohen, M. H., G. Williams, J. R. Johnson, J. Duan, J. Gobburu, A. Rahman, K. Benson, J. Leighton, S. K. Kim, R. Wood, M. Rothmann, G. Chen, K. M. U, A.M. Staten, and R. Pazdur, Approval Summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia, Clin. Cancer Res. 5 (2002), 935-942.
12. Cuervo, A. M. and J. F. Dice, Lysosomes, a meeting point of proteins, chaperones, and proteases, J. Mol. Med. 76 (1998), 6-12.
13. Daley, G. Q., R. A. Van Etten, and D. Baltimore, Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome, Science 247 (1990), 824-830.
14. Danial, N. N., A. Pernis, and P. B. Rothman, Jak-STAT signaling induced by the v-abl oncogene, Science 269 (1995), 1875-1877.
15. Deininger, M. W. N., J. M. Goldman, and J. V. Melo, The molecular biology of chronic myeloid leukemia, Blood 96 (2000), 3343-3356.
16. Dhut, S., T. Chaplin, and B. D. Young, BCR-ABL and BCR proteins: biochemical characterization and localization, Leukemia 4 (1990), 745-50.
17. Druker, B. J., S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann, and N. B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat. Med. 2 (1996), 561-566.
18. Druker, B. J., STI571 (Gleevec) as a new paradigm for cancer therapy, Trends. Mol. Med. 8 (2002), S14-S18.
19. Eaves, C. J., J. Cashman, and A. C. Eaves, Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia, Leuk. Res. 22 (1998), 1085-1096.
20. Fader, S., M. Talpaz, Z. Estrov, S. O'Brien, R. Kurzrock, and H. M. Kantarjian, The biology of chronic myeloid leukemia, N. Engl. J. Med. 341 (1999), 164-172.
21. Gambacorti-Passerini, C., R. Barni, P. le Coutre, M. Zucchetti, G. Cabrita, L. Cleris, F. Rossi, E. Gianazza, J. Brueggen, R. Cozens, P. Pioltelli, E. Pogliani, G. Corneo, F. Formelli, and M. D'Incalci, Role of alphal acid glycoprotein in the in vivo resistance of human Bcr-Abl-positive leukemic cells to the Abl inhibitor STI571, J. Natl. Cancer Inst. 92 (2000), 1641-1650.
22. Glickman, M. H. and A. Ciechanover, The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction, Physiol Rev. 82 (2002), 373-428.
23. Gorre, M. E., M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P. N. Rao, and C. L. Sawyers, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science 293 (2001), 876-80.
24. Heinrich, M. C., D. J. Griffith, B. J. Druker, C. L. Wait, K. A. Ott, and A. J. Zigler, Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor, Blood 96 (2000), 925-932.
25. Holyoake, T. L., X. Jiang, M. W. Drummond, A. C. Eaves, and C. J. Eaves, Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia, Leukemia 16 (2002), 549-558.
26. Ilaria Jr., R. L. and R. A. Van Etten, P210 and P190(Bcr/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members, J. Biol. Chem. 271 (1996), 31704-31710.
27. Jørgensen, H. G. and T.L. Holyoake, A comparison of normal and leukemic stem cell biology in chronic myeloid leukemia, Hematol. Oncol. 19 (2001), 89-106.
28. Kantarjian, H. M., S. O'Brien, J. E. Cortes, S. A. Giralt, M. B. Rios, J. Shan, F. J. Giles, D. A. Thomas, S. Faderl, M. De Lima, G. Garcia-Manero, R. Champlin, R. Arlinghaus, and M. Talpaz, Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia, Blood 100 (2002), 1590-1595.
29. le Coutre, P. L., L. Mologni, L. Cleris, E. Marchesi, E. Buchdunger, R. Giardini, F. Formelli, and C. Gambarcorti-Passerini, In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor, J. Natl. Cancer. Inst. 91 (1999), 163-168.
30. Mahon, F., F. Belloc, V. Lagarde, C., F. Moreau-Gaudry, J. Reiffers, J. M. Goldman, and J. V. Melo, MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models, Blood 101 (2003), 2368-2373.
31. Mandanas, R. A., D. S. Leibowitz, K. Gharehbaghi, T. Tauchi, G. S. Burgess, K. Miyazawa, H. N. Jayaram, and H. S. Boswell, Role of p21 ras in p210 bcr-abl transformation of murine myeloid cells, Blood 82 (1993), 1838-1847.
32. Matsuda, M., S. Ota, R. Tanimura, H. Nakamura, K. Matuoka, T. Takenwawa, K. Nagashima, and T. Kurata, Interaction between amino-terminal SH3 domain of Crk and its natural target proteins, J. Biol Chem. 271 (1996), 14468-14472.
33. Mayover, T. L., C. J. Halkides, and R. C. Stewart, Kinetic characterization of CheY phosphorylation reactions: comparison of P-CheA and small molecule phosphodonors, Biochemistry 38 (1999), 2259-2271.
34. Nichols, G. L., M. A. Raines, J. C. Vera, L. Lacomis, P. Tempst, and D. W. Golde, Identification of Crkl as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells, Blood 84 (1994), 2912-2918.
35. Oda, H., C. Heaney, J. R. Hagopian, K. Okusa, J. D. Griffin, and B. J. Druker, Crkl is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia, J. Biol. Chem. 269 (1994), 22925-22928.
36. Puil, L., J. Liu, G. Gish, G. Mbamalu, D. Bowtell, P. G. Pelicci, R. Arlinghaus, and T. Pawson, Bcr-Abl oncoproteins bind directly to activators of the Ras signaling pathway, EMBO J. 13 (1994), 764-773.
37. Raitano, A. B., J. R. Halpern, T. M. Hambuch, and C. L. Sawyers, The Bcr-ABL leukemia oncogene activates Jun kinase and requires Jun for transformation, Proc. Natl. Acad. Sci. USA 92 (1995), 11746-11750.
38. Rowley, J. D., A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining, Nature 243 (1973), 290-293.
39. Sawyers, C. L., Chronic myeloid leukemia, N. Engl. J. Med. 340 (1999), 1330-1340.
40. Schindler, T., W. Bornmann, P. Pellicena, W. T. Miller, B. Clarkson, and J. Kuriyan, Structural mechanism for STI-571 inhibition of abelson tyrosine kinase, Science 289 (2000), 1938-1942.
41. Shargel, L. and A. B. C. Yu, Applied Biopharmaceutics and Pharmacokinetics, McGraw-Hill/Appleton & Lange, 1999
42. Sharom, F. J., The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. 160 (1997), 161-175.
43. Shet, A. S., B. N. Jahagirdar, and C. N. Verfaillie, Chronic myelogenous leukemia: mechanisms underlying disease progression, Leukemia 16 (2002), 1402-1411.
44. Skamnaki, V. T., D. J. Owen, M. E. M. Noble, E. D. Lowe, G. Lowe, N. G. Oikonomakos, and L. N. Johnson, Catalytic mechanism of phosphorylase kinase probed by mutational studies, Biochemistry 38 (1999), 14718-14730.
45. Skorski, T., P. Kanakaraj, M. Nieborowska-Skorska, M. Z. Ratajczak, S.-C. Wen, G. Zon, A. M. Gewirtz, B. Perussia, and B. Calabretta, Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells, Blood 86 (1995), 726-736.
46. Storn, R. and K. Price, Differential Evolution A simple and efficient heuristic for global optimization over continuous spaces, J. Global Optim. 11 (1997), 341-359.
47. Tawa, P. and R. C. Stewart, Kinetics of CheA autophosphorylation and dephosphorylation reactions, Biochemistry 33 (1994), 7917-7924.
48. ten Hoeve, J., R. B. Arlinghaus, J. Q. Guo, N. Heisterkamp, and J. Groffen, Tyrosine phosphorylation of Crkl in Philadelphia+ leukemia, Blood 84 (1994), 1731-1736.
49. Tomasson, M. H., I. R. Williams, R. Hasserjian, C. Udomsakdi, S. M. McGrath, J. Schwaller, B. Druker, and D. G. Gilliland, TEL/PDGFbR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor, Blood 93 (1999), 1707-1714.
50. Twentyman, P. R., Transport proteins in drug resistance: biology and approaches to circumvention, J. Intern. Med. Suppl. 740 (1997), 133-137.
51. Warmuth, M., S. Danhauser-Riedl, and M. Hallek, Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies, Ann. Hematol. 78 (1999), 49-64.
52. Zhou, J. and J. A. Adams, Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase, Biochemistry 36 (1997), 15733-15738.